

# A One Health approach to COVID-19 research in the UK

Eleanor Riley Institute of Immunology and Infection Research



THE UNIVERSITY of EDINBURGH


## Learning from animal coronaviruses: 1 Virus emergence and evolution



- **Coronaviruses have regularly and repeatedly emerged** in new host species, often via virus recombination within an <u>intermediate host</u>, e.g.
  - <u>cattle</u> for HCoV OC43 (1890s)
  - camels for HuCoV 229E and MERS (2010s)
  - <u>civet</u> for SARS (2000s)
- East Asia is a hotspot for emergence of coronaviruses, in pigs as well as humans. E.g. in pigs: porcine epidemic diarrhoea virus (PEDV), transmissible gastroenteritis virus (TGEV), porcine deltacoronavirus (PDCoV), and severe acute diarrhoea syndrome (SADS-CoV; 2017)
- Human CoVs have been historically poorly studied as they "just" cause common cold. E.g we don't know how HCoV OC43 has evolved in the last 100 years if we did it might help us predict what will happen to SARS-CoV-2.
- Evidence for cross-protection between CoV species, e.g. porcine respiratory coronavirus (PRCV) cross protects vs TGEV, as both viruses endemic world wide TGEV has become less of a clinical problem

Learning from animal coronaviruses: 2

## Pathophysiology: variation in disease presentation/severity




- canine respiratory betacoronavirus:
  - asymptomatic, or kennel cough, or severe bronchopneumonia;
- bovine CoV:
  - dysentery, respiratory symptoms, pneumonia, fever
- porcine respiratory coronavirus:
  - clinically mild respiratory infection or pneumonia
- feline alphacoronavirus:
  - mild disease; virus accumulates in-host mutations to cause feline infectious peritonitis, similar pathophysiology to pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS)

## Learning from animal coronaviruses: 3 Vaccines

- effective vaccines exist to protect against CoVs in cats, dogs and livestock
- vaccines remain effective for decades, indicating slow evolution and lack of viral escape
- live attenuated (e.g. porcine TGEV) and inactivated (e.g. porcine SADS and bovine CoV) whole virus vaccines can work
- antibodies and cellular immunity both important.
- passive immunity conferred by neutralising Ab in milk.
- **but**: avian infectious bronchitis virus (IBV) virus attenuation provides poor cross protection, reversion to virulence, and varying efficacy; full length spike vectored vaccine is more protective than subunit vaccines but still limited cross protection.

### **Animal models**

- Conserved biology of CoVs using animal viruses to screen antivirals
- Vaccine immunogenicity testing in pigs: ChAdOx1 nCoV-19 (AZD1222) vaccine two doses better than one




Graham et al; www.biorxiv.org/content/10.1101/2020.06.20.159715v1

## Planning ahead: UK Vaccines R&D Network

- Established in 2016 post Ebola, co-incident with Zika
- Members from medical and veterinary vaccines research and manufacturing communities
- Agreed a prioritised list of pathogens with epidemic potential for which we lack vaccines, included MERS and "disease X"
- Developed a decision tree to determine relevance of emergency vaccine development in any particular outbreak scenario
- Developed a tool to identify bottlenecks for vaccine development and manufacture
- Conducted a review of vaccine manufacturing capacity in UK
- Provided £110M funding for
  - Research on One Health approaches to vaccine development; vaccine epidemiology; vaccine development for priority diseases; novel vaccine platforms (including ChAdOx and RNA vaccines); post vaccination Guillain-Barre syndrome; manufacturing
  - Future Vaccine Manufacturing Research Hub
  - Vaccines Manufacturing Innovation Centre

## Funding and Policy



#### UK Research and Innovation (UKRI) COVID-19 Taskforce:

 bringing together researchers across all disciplines (including social sciences, humanities, economics, physical sciences as well as biological, biomedical and clinical) with government agencies and SAGE

#### Direct funding from government:

• Epidemiology; clinical studies; clinical trials; vaccine, diagnostics and drug development

#### Rapid Response funding:

- £50M via UKRI for research with public health impact within 12 months
- £20M joint funding UKRI and Department of Health and Social Care
- new tranche of funds expected this month

#### Coordination:

• portfolio review, gap identification, commissioning research to fill gaps

#### Current gap:

 human-animal interface, potential for reverse zoonosis, establishment of new animal reservoirs of infection

## One Health approach in Edinburgh:

#### Moredun Research Institute and Scotland's Rural College (SRUC)

• Providing capacity for SARS-CoV-2 virus diagnostics

Roslin Institute conducting research on

- Virus dissemination in waste water (with Scottish Water)
- Functional genomics of SARS-CoV-2
- Construction of pseudoviruses for drug screening
- Expression of SARS-CoV-2 spike proteins in influenza A and rotavirus vaccine mimics
- Tracking virus transmission via virus phylogeny
- Generating a hACE2 gene edited pig as a large animal model of Covid-19
- Adapting EPIC livestock disease simulation models to inform disease control policy and assess the unique risks to Scotland's demography
- Develoing an epidemiological decision support toolbox to inform policy and decision making in Uganda and Kenya

#### Global Academy of Agriculture and Food Security

 Assessing the socio-economic impact of COVID-19 and the lockdown on food security, e.g. on broiler and fish value chains in India and Bangladesh



## Can we do better?

The international research community has "played a blinder"

In 6 months, we have

- identified and sequenced the virus (thousands of times) and mapped its spread
- initiated > 200 vaccine development programmes with at least 5 in human trials
- significantly improved case management
- But, we still don't know
  - why some people are severely ill whilst others are very mildly affected
  - is there protective immunity and how long does it last?
  - will any of the vaccines work and if so, why?
  - is the virus evolving or just drifting?
  - where did the virus come from?

A One Health approach can help (or is essential) to answer all of these questions





